Artiva Biotherapeutics, Inc.
NASDAQ:ARTV · NASDAQ Global Market
-$0.34 today
Vol 1.75M · Avg 0.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.3%
avg 16.5%
ROIC
-74.9%
avg -43.7%
ROA
-64.0%
avg -38.0%
Analysis
ROA is currently the strongest return metric at -64.0% versus its period average of -38.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Fred Aslan | CEO, Principal Financial & Accounting Officer and Director | $1.22M | — | 51 | $1.54M | 6.21% |
Jennifer Kinsbruner Bush | Chief Operating Officer | $839,214.00 | — | 51 | $337,920.00 | 1.37% |
Christopher Horan | Chief Technical Operations Officer | $777,619.00 | — | 59 | $293,450.00 | 1.19% |
Peter Flynn | Co-Founder & Strategic Advisor | $499,368.00 | — | 52 | — | — |
Gines Diego Miralles | President and Head of Research & Development | $55,000.00 | — | 63 | $77,500.00 | 0.31% |
Heather Raymon | Senior Vice President of Research & Early Development | — | — | 61 | $148,228.00 | 0.60% |
Nicholas Veomett | Vice President of Corporate Development | — | — | — | — | — |
Subhashis Banerjee | Chief Medical Officer | — | — | 69 | $144,963.00 | 0.59% |
Andrew Cronauer | VP, General Counsel & Corporate Secretary | — | — | — | — | — |
Benjamin Dewees | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Feng Xu | Senior Vice President of Biometrics | — | — | — | — | — |
Thad Huston | CFO and Principal Financial & Accounting Officer | — | — | 55 | $220,000.00 | 0.89% |
David Moriarty | Senior Vice President of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$103.75M
Sells
9
$740,992.89
Net Sentiment
+$103.01M
Net buying
Most Active
RA CAPITAL MANAGEMENT, L.P.
8 transactions
1–10 of 19
Analysis
Insiders reported 10 buys worth $103.75M and 9 sells worth $740,992.89 over the last 12 months. That adds up to net buying of $103.01M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -50.0% | +206.3% (6yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -50.0% over three years. Forward estimates point to Revenue at +206.3% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.12M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$260.16M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.42M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$190.41M
InflaRx N.V.
NASDAQ:IFRX
$129.66M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.30M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Precision BioSciences, Inc.
NASDAQ:DTIL
$84.54M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$60.64M
Metagenomi, Inc. Common Stock
MGX
$44.99M
Who manages ARTV?
Artiva Biotherapeutics, Inc. (ARTV) lists 13 active executives. The top listed executive is Fred Aslan, CEO, Principal Financial & Accounting Officer and Director.
Are ARTV insiders buying or selling?
Recent insider activity shows net buying of $2.17T.
Explore More
Continue the stock analysis
Jump to another research area for this company.